LL-37
37-residue human cathelicidin antimicrobial peptide studied in innate-immunity and wound-healing research.
37-residue human cathelicidin antimicrobial peptide studied in innate-immunity and wound-healing research.
The primary literature on this compound includes Vandamme et al., Cell Immunol (2012). The references below link directly to the published record.
Every lot is synthesized in the USA, verified by HPLC, and ships with its Certificate of Analysis. It is supplied strictly for laboratory research use.
Research use only. Everything on this page describes laboratory research. This compound is supplied strictly for in-vitro research use; it is not approved by the FDA for human or veterinary use, and nothing here is a protocol or a recommendation.
Published research
- The Human Cathelicidin Antimicrobial Peptide LL-37 as a Potential Treatment for Polymicrobial Infected WoundsMcCrudden MT, et al. Pharmaceutics. 2013.PubMed →
- A comprehensive summary of LL-37, the factotum human cathelicidin peptideVandamme D, et al. Cell Immunol. 2012.PubMed →
- The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epitheliumHeilborn JD, et al. J Invest Dermatol. 2003.PubMed →
- In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37
Further reading in the lab library
Researchers also ordered
- BPC-15715-amino-acid synthetic pentadecapeptide derived from body-protection compound. Tissue-repair research peptide.
- GHK-CuCopper tripeptide-1. Studied in extracellular-matrix and fibroblast research.
- KPVC-terminal α-MSH tripeptide studied in inflammation and gut-mucosal research.
- PEG-MGFPEGylated mechano-growth-factor analog studied in muscle-tissue signalling research.